Literature DB >> 9047370

The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence.

M G Malkowski1, J B Lazar, P H Johnson, B F Edwards.   

Abstract

alpha-Chemokines comprise a family of cytokines that are chemotactic for neutrophils and have a structure similar to platelet factor 4 (PF4), in which the first two cysteine residues are separated by one residue (Cys-X-Cys). The two alpha-chemokines, connective tissue activating peptide-III (CTAP-III) and neutrophil activating peptide-2 (NAP-2), are carboxyl-terminal fragments of platelet basic protein (PBP) that are generated by monocyte-derived proteases. NAP-2 strongly stimulates neutrophils that are present during inflammation whereas its precursors, PBP and CTAP-III, are inactive, although they also possess the highly conserved, amino-terminal sequence, Glu-Leu-Arg (ELR), that is critical for receptor binding. To resolve this conundrum, we have determined the crystal structure of recombinant Asp-CTAP, which has ten fewer amino-terminal residues than CTAP-III but five more than NAP-2. The space group is P2(1)with unit cell dimensions a = 43.8 A, b = 76.8 A, c = 43.8 A, and beta =97.0 degrees, and a tetramer in the asymmetric unit. The molecular replacement method, with the NAP-2 tetramer as a starting model, was used to determine the initial phase information. The final R-factor is 0.196 (Rfree = 0.251) for 2sigma data from 7.0 to 1.75 A resolution. This high-resolution model of Asp-CTAP is the longest defined structure of an alpha-chemokine to date. The electron density map shows an over-all structure for Asp-CTAP that is very similar to that of NAP-2, but with the additional five amino-terminal residues folding back through a type-II turn, thereby stabilizing the oligomeric "inactive" state, and masking the critical ELR receptor binding region that is exposed in the structure of NAP-2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047370     DOI: 10.1006/jmbi.1996.0796

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis.

Authors:  Eva A V Moelants; Gitte Loozen; Anneleen Mortier; Erik Martens; Ghislain Opdenakker; Danuta Mizgalska; Borys Szmigielski; Jan Potempa; Jo Van Damme; Wim Teughels; Paul Proost
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 2.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  Gingipains from Porphyromonas gingivalis increase the chemotactic and respiratory burst-priming properties of the 77-amino-acid interleukin-8 variant.

Authors:  Irundika H K Dias; Lindsay Marshall; Peter A Lambert; Iain L C Chapple; John B Matthews; Helen R Griffiths
Journal:  Infect Immun       Date:  2007-11-19       Impact factor: 3.441

Review 4.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

Review 5.  Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.

Authors:  Qianmiao Wu; Huaijun Tu; Jian Li
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

6.  SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines.

Authors:  Arne Egesten; Anders I Olin; Helena M Linge; Manisha Yadav; Matthias Mörgelin; Anna Karlsson; Mattias Collin
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

7.  SufA of the opportunistic pathogen finegoldia magna modulates actions of the antibacterial chemokine MIG/CXCL9, promoting bacterial survival during epithelial inflammation.

Authors:  Christofer Karlsson; Mette Eliasson; Anders I Olin; Matthias Mörgelin; Anna Karlsson; Martin Malmsten; Arne Egesten; Inga-Maria Frick
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.